Related Experiment Video

Updated: Dec 19, 2025

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

371

First 1.5 years of pegvaliase clinic: Experiences and outcomes

Stephanie Sacharow1, Cassandra Papaleo2, Kyla Almeida2

  • 1Department of Pediatrics, Harvard Medical School, Boston, MA, United States of America.

Molecular Genetics and Metabolism Reports
|June 4, 2020
PubMed

Insights

Boston Children's Hospital

Area of Science:

  • Biochemistry
  • Metabolic Disorders
  • Pharmacology

Background:

  • Phenylketonuria (PKU) is a rare genetic disorder.
  • Elevated phenylalanine (Phe) levels can cause severe health issues.
  • Current PKU management often involves strict dietary restrictions.

Purpose of the Study:

  • To describe Boston Children's Hospital's clinical model for pegvaliase therapy in adults with PKU.
  • To report clinical outcomes of pegvaliase treatment in adult PKU patients.
  • To assess the efficacy and safety of pegvaliase in a real-world setting.

Main Methods:

  • Retrospective analysis of 46 adult PKU patients treated with pegvaliase.
  • Data collected over the first 1.5 years of commercial pegvaliase therapy.
  • Monitoring of blood phenylalanine levels and side effect management.

Main Results:

  • 70% of patients initiating pegvaliase achieved blood Phe <360 μmol/L.
  • Average reduction in blood Phe from baseline was 68% ± 24%.
  • All patients experienced side effects, with most managed to allow continued treatment.

Conclusions:

  • Pegvaliase therapy, managed by a specialized clinic model, is effective in reducing blood Phe levels in adults with PKU.
  • While side effects are common, they are generally manageable, allowing for sustained treatment.
  • This model provides a framework for optimizing pegvaliase treatment outcomes in PKU patients.

More Related Videos

Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture05:33

Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture

Published on: August 4, 2023

2.1K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.3K

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
216
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
368
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
362
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
234
Proliferative Phase01:20

Proliferative Phase

The proliferative phase typically occurs after menstruation and lasts between 6 to 13 days in a standard 28-day cycle. This phase involves the reconstruction of the endometrium, guided by estrogen produced by the developing ovarian follicle.
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...
1.1K